Form 8-K - Current report:
SEC Accession No. 0001213900-25-012213
Filing Date
2025-02-11
Accepted
2025-02-11 16:12:36
Documents
15
Period of Report
2025-02-11
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ea023067101-8k425_denalicap.htm   iXBRL 8-K 30875
2 PRESS RELEASE, DATED FEBRUARY 11, 2025 ea023067101ex99-1_denalicap.htm EX-99.1 4432
  Complete submission text file 0001213900-25-012213.txt   265471

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE deca-20250211.xsd EX-101.SCH 4173
4 XBRL DEFINITION FILE deca-20250211_def.xml EX-101.DEF 27298
5 XBRL LABEL FILE deca-20250211_lab.xml EX-101.LAB 37879
6 XBRL PRESENTATION FILE deca-20250211_pre.xml EX-101.PRE 25918
17 EXTRACTED XBRL INSTANCE DOCUMENT ea023067101-8k425_denalicap_htm.xml XML 7468
Mailing Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022
Business Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022 6469785180
Denali Capital Acquisition Corp. (Filer) CIK: 0001913577 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41351 | Film No.: 25609938
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)